|
1
|
Vangeldorp M, Jamieson WRE, Kappetein AP,
Ye J, Fradet GJ, Eijkemans MJC, Grunkemeier GL, Bogers JJC and
Takkenberg JJM: Patient outcome after aortic valve replacement with
a mechanical or biological prosthesis: Weighing lifetime
anticoagulant-related event risk against reoperation risk. J Thorac
Cardiovasc. 37:881–886. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rodeghiero F, Stasi R, Gernsheimer T,
Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH,
Cooper N, et al: Standardization of terminology, definitions and
outcome criteria in immune thrombocytopenic purpura of adults and
children: Report from an international working group. Blood.
113:2386–2393. 2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Neylon AJ, Saunders PW, Howard MR, Proctor
SJ and Taylor PR: Northern Region Haematology Group: Clinically
significant newly presenting autoimmune thrombocytopenic purpura in
adults: A prospective study of a population-based cohort of 245
patients. Br J Haematol. 122:966–974. 2003.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Abrahamson PE, Hall SA, Feudjo-Tepie M,
Mitrani-Gold FS and Logie J: The incidence of idiopathic
thrombocytopenic purpura among adults: A population-based study and
literature review. Eur J Haematol. 83:83–89. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
McCrae K: Immune thrombocytopenia: No
longer ‘idiopathic’. Cleve Clin J Med. 78:358–373. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Piccardo A, Rusinaru D, Petitprez B,
Marticho P, Vaida I, Tribouilloy C and Caus T: Thrombocytopenia
after aortic valve replacement with freedom solo bioprosthesis: A
propensity study. Ann Thorac Surg. 89:1425–1430. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mujtaba SS, Ledingham S, Shah AR, Schueler
S, Clark S and Pillay T: Thrombocytopenia after aortic valve
replacement: Comparison between sutureless perceval S Valve and
Perimount Magna Ease Bioprosthesis. Braz J Cardiovasc Surg.
33:169–175. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kizilay M, Elbir F, Aglar AA, Vural U,
Balci AY and Yekeler İ: An overlooked fact: Thrombocytopenia
following bioprosthetic aortic valve replacement. Kardiochir
Torakochirurgia Pol. 16:19–26. 2019.(In Polish). PubMed/NCBI View Article : Google Scholar
|
|
9
|
Corbett TL, Elher KS and Garwood CL:
Successful use of fondaparinux in a patient with a mechanical heart
valve replacement and a history of heparin-induced
thrombocytopenia. J Thromb Thrombolysis. 30:375–377.
2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Warkentin TE, Greinacher A, Koster A and
Lincoff AM: Treatment and prevention of heparin-induced
thrombocytopenia. American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th Edition). Chest.
133:S340–S380. 2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Emery RW, Krogh CC, Arom KV, Emery AM,
Benyo-Albrecht K, Joyce LD and Nicoloff DM: The St. Jude Medical
cardiac valve prosthesis: A 25-year experience with single valve
replacement. Ann Thorac Surg. 79:776–782; discussion 782-783.
2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Salem DN, O'Gara PT, Madias C and Pauker
SG: Valvular and structural heart disease: American College of
Chest Physicians Evidence-Based Clinical Practice Guidelines (8th
edition). Chest. 133:S593–S629. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tardalkar K, Desai S, Adnaik A, Bohara R
and Joshi M: Novel approach toward the generation of tissue
engineered heart valve by using combination of antioxidant and
detergent: A potential therapy in cardiovascular tissue
engineering. Tissue Eng Regen Med. 14:755–762. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhang BL, Bianco RW and Schoen FJ:
Preclinical assessment of cardiac valve substitutes: Current status
and considerations for engineered tissue heart valves. Front
Cardiovasc Med. 6(72)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Movileanu I, Brinzaniuc K, Harpa M, Nistor
D, Cotoi O, Preda T, Al Hussein H, Moldovan O, Man A, Harceaga L,
et al: Pressurized perfusion system for obtaining completely
acellular pulmonary valve scaffolds for tissue engineering. ARS Med
Tomitana. 25:149–156. 2019.
|
|
16
|
Harpa M, Movileanu I, Sierad L, Cotoi O,
Suciu H, Preda T, Nistor D, Sircuța C, Brânzaniuc K, Deac R, et al:
In vivo testing of xenogeneic acellular aortic valves seeded with
stem cells. Rev Rom Med Lab. 24:343–346. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Reimer J, Syedain Z, Haynie B, Lahti M,
Berry J and Tranquillo R: Implantation of a tissue-engineered
tubular heart valve in growing lambs. Ann Biomed Eng. 45:439–451.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Boethig D, Horke A, Hazekamp M, Meyns B,
Rega F, Van Puyvelde J, Hübler M, Schmiady M, Ciubotaru A, Stellin
G, et al: A European study on decellularized homografts for
pulmonary valve replacement: Initial results from the prospective
ESPOIR Trial and ESPOIR Registry data. Eur J Cardio-Thorac Surg.
56:503–509. 2019.PubMed/NCBI View Article : Google Scholar
|
